Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

MELBOURNE, Australia and SAN FRANCISCO: Highlights: Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence with Alterity's plan to target early stage MSA patients. Endorsement on selection of biomarker endpoints to assess...

Click to view original post